This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Park, S.-Y. Articles by Park, Y.-M. Search for Related Content PubMed PubMed Citation Articles by Park, S.-Y. Articles by Park, Y.-M.

Hypoxia Increases Androgen Receptor Activity in Prostate Cancer Cells

Departments of ¹ Cell Stress Biology, ² Medicine, ³ Urologic Oncology, and ⁴ Cancer Chemoprevention, Roswell Park Cancer Institute, Buffalo, New York

Requests for reprints: Young-Mee Park, Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY 14263. Phone: 716-845-3190; Fax: 716-845-8899; E-mail: young-mee.park{at}roswellpark.org.

Recent studies show that prostate cancer cells are able to survive in a hypoxic tumor environment, and the extent of tumor hypoxia correlates with poor clinical outcome. Androgen deprivation, the most common form of prostate cancer therapy, was itself shown to induce a state of transient hypoxia at the microenvironmental level. Because androgen receptor (AR) signaling plays a critical role in prostate cancer, we investigated the effect of hypoxia in regulating AR function. We found that in LNCaP prostate cancer cells, AR binding to the androgen-responsive element (ARE), prostate-specific antigen accumulation, and ARE-reporter gene activity were increased after hypoxia treatment. Hypoxia-enhanced AR function was also observed when AR was exogenously introduced into AR-null DU145 cells. Confocal microscopy and chromatin immunoprecipitation assays showed that AR translocation to the nucleus and AR recruitment to the prostate-specific antigen promoter were facilitated after hypoxia treatment. The AR stimulatory effect seemed to be ligand-dependent because it was abrogated when cells were cultured in an androgen-depleted medium, but was restored with the addition of R1881, a synthetic androgen. The sensitivity of AR activation to R1881 was also increased after hypoxia treatment. Although concentrations of <1 nmol/L R1881 did not induce ARE reporter activity under normoxic conditions, exposure to hypoxia greatly potentiated the AR response to low levels of R1881. Collectively, our results provide compelling evidence that changes in hypoxia/reoxygenation stimulate AR trans-activation and sensitization. The AR-stimulatory effect of an unstable tissue oxygenation milieu of a tumor is likely to contribute to treatment resistance and the emergence of recurrent prostate cancer. (Cancer Res 2006; 66(10): 5121-9)

This article has been cited by other articles:

				R. R. Chhipa, K.-S. Lee, S. Onate, Y. Wu, and C. Ip Prx1 Enhances Androgen Receptor Function in Prostate Cancer Cells by Increasing Receptor Affinity to Dihydrotestosterone Mol. Cancer Res., September 1, 2009; 7(9): 1543 - 1552. [Abstract] [Full Text] [PDF]

				S.-Y. Park, X. Yu, C. Ip, J. L. Mohler, P. N. Bogner, and Y.-M. Park Peroxiredoxin 1 Interacts with Androgen Receptor and Enhances Its Transactivation Cancer Res., October 1, 2007; 67(19): 9294 - 9303. [Abstract] [Full Text] [PDF]

				M. Milosevic, P. Chung, C. Parker, R. Bristow, A. Toi, T. Panzarella, P. Warde, C. Catton, C. Menard, A. Bayley, et al. Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response Cancer Res., July 1, 2007; 67(13): 6022 - 6025. [Abstract] [Full Text] [PDF]

				Y.-J. Kim, J.-Y. Ahn, P. Liang, C. Ip, Y. Zhang, and Y.-M. Park Human prx1 Gene Is a Target of Nrf2 and Is Up-regulated by Hypoxia/Reoxygenation: Implication to Tumor Biology Cancer Res., January 15, 2007; 67(2): 546 - 554. [Abstract] [Full Text] [PDF]